Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Liraglutide
Drug ID BADD_D01298
Description Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist[Label,A6932]. Liraglutide is 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34[A6932]. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor[A6932]. Liraglutide was granted FDA approval on Januray 25, 2010[L6070].
Indications and Usage For use in/treatment of diabetes mellitus type 2.
Marketing Status Prescription
ATC Code A10BJ02
DrugBank ID DB06655
KEGG ID D06404
MeSH ID D000069450
PubChem ID 16134956
TTD Drug ID D03GOI
NDC Product Code 66558-0193; 69766-034; 0169-4060; 71796-022; 73569-007; 32861-0003; 50090-4503; 52221-122; 65129-1375; 50090-4257; 70155-003; 50090-2853; 41524-0011; 14403-0009; 76177-118; 0169-2800; 66558-0181; 0420-9006
Synonyms Liraglutide | Victoza | Saxenda | NN 2211 | 2211, NN | NN2211 | NN-2211
Chemical Information
Molecular Formula C172H265N43O51
CAS Registry Number 204656-20-2
SMILES CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O) NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O )NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O )C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O )C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C( CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6) N)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.002--
Eructation07.01.02.003--
Erythema23.03.06.001--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastroenteritis viral07.19.03.005; 11.05.04.005--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Headache17.14.01.001--
Heart rate increased13.14.04.002--Not Available
Hepatitis09.01.07.004--Not Available
Hyperbilirubinaemia14.11.01.010; 01.06.04.003; 09.01.01.003--Not Available
Hypersensitivity10.01.03.003--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Injection site dermatitis12.07.03.041; 08.02.03.041; 23.03.04.033--Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Intestinal obstruction07.13.01.002--Not Available
Lipase increased13.05.01.003--
Malaise08.01.01.003--
Medullary thyroid cancer16.24.03.004; 05.02.05.007--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages